Alder Biopharmaceuticals (ALDR) PT Lowered to $17.00 at Credit Suisse Group

Alder Biopharmaceuticals (NASDAQ:ALDR) had its price target cut by Credit Suisse Group from $19.00 to $17.00 in a research note issued to investors on Tuesday. They currently have a hold rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. BidaskClub lowered Alder Biopharmaceuticals from a buy rating to a hold rating in a research report on Friday, August 17th. BMO Capital Markets boosted their target price on Alder Biopharmaceuticals from $21.00 to $23.00 and gave the company a buy rating in a research report on Wednesday, August 8th. ValuEngine raised Alder Biopharmaceuticals from a buy rating to a strong-buy rating in a research report on Thursday, August 2nd. Cantor Fitzgerald reissued a hold rating and issued a $21.00 target price on shares of Alder Biopharmaceuticals in a research report on Tuesday, October 23rd. Finally, Zacks Investment Research lowered Alder Biopharmaceuticals from a buy rating to a hold rating in a research report on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $21.67.

NASDAQ ALDR traded down $0.15 on Tuesday, reaching $13.88. The stock had a trading volume of 706,563 shares, compared to its average volume of 800,551. The firm has a market cap of $996.89 million, a price-to-earnings ratio of -2.80 and a beta of 2.70. The company has a quick ratio of 10.88, a current ratio of 15.34 and a debt-to-equity ratio of 0.97. Alder Biopharmaceuticals has a 12-month low of $9.55 and a 12-month high of $20.87.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.22. Analysts anticipate that Alder Biopharmaceuticals will post -4.47 EPS for the current fiscal year.

In other news, insider John A. Latham sold 24,999 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $17.99, for a total transaction of $449,732.01. Following the sale, the insider now owns 268,692 shares of the company’s stock, valued at $4,833,769.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John A. Latham sold 25,002 shares of the company’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $13.42, for a total value of $335,526.84. Following the sale, the insider now directly owns 250,514 shares in the company, valued at approximately $3,361,897.88. The disclosure for this sale can be found here. Insiders have sold 90,120 shares of company stock worth $1,407,922 in the last ninety days. Corporate insiders own 17.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of ALDR. Dimensional Fund Advisors LP increased its position in shares of Alder Biopharmaceuticals by 39.2% during the first quarter. Dimensional Fund Advisors LP now owns 822,784 shares of the biopharmaceutical company’s stock worth $10,449,000 after acquiring an additional 231,859 shares during the period. UBS Group AG grew its stake in shares of Alder Biopharmaceuticals by 1,284.0% during the first quarter. UBS Group AG now owns 228,837 shares of the biopharmaceutical company’s stock worth $2,906,000 after purchasing an additional 212,303 shares in the last quarter. LPL Financial LLC acquired a new position in shares of Alder Biopharmaceuticals during the first quarter worth $156,000. Legal & General Group Plc grew its stake in shares of Alder Biopharmaceuticals by 31.1% during the first quarter. Legal & General Group Plc now owns 25,547 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 6,060 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Alder Biopharmaceuticals by 68.6% during the first quarter. Royal Bank of Canada now owns 56,810 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 23,121 shares in the last quarter.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Featured Article: What is a Swap?

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit